within Pharmacolibrary.Drugs.ATC.D;

model D05AX03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 9.999999999999999e-06,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00415,
    Tlag           = 19.98,            
    Vdp             = 0.011,
    k12             = 0.5,
    k21             = 0.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D05AX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Calcitriol is the active form of vitamin D3 (1,25-dihydroxycholecalciferol). It is primarily used to manage hypocalcemia, secondary hyperparathyroidism, and metabolic bone diseases such as osteoporosis and chronic kidney disease. Calcitriol is an approved drug, used in both oral and intravenous forms.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Levine, BS, &amp; Song, M (1996). Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. <i>Journal of the American Society of Nephrology : JASN</i> 7(3) 488–496. DOI:<a href=\"https://doi.org/10.1681/ASN.V73488\">10.1681/ASN.V73488</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8704116/\">https://pubmed.ncbi.nlm.nih.gov/8704116</a></p></li><li><p>Muindi, JR, et al., &amp; Trump, DL (2002). Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. <i>Clinical pharmacology and therapeutics</i> 72(6) 648–659. DOI:<a href=\"https://doi.org/10.1067/mcp.2002.129305\">10.1067/mcp.2002.129305</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12496746/\">https://pubmed.ncbi.nlm.nih.gov/12496746</a></p></li><li><p>Pierce, D, et al., &amp; Smyth, M (2011). The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 26(5) 1615–1621. DOI:<a href=\"https://doi.org/10.1093/ndt/gfq598\">10.1093/ndt/gfq598</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20921291/\">https://pubmed.ncbi.nlm.nih.gov/20921291</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D05AX03;
